Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
narmafotinib
- Development stage
- Phase 2
- Lead developer
- Amplia Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Narmafotinib is a highly potent and selective, orally bioavailable small molecule inhibitor of focal adhesion kinase (FAK), a non-receptor tyrosine kinase overexpressed in several cancers, including pancreatic cancer. FAK plays a key role in tumor growth by promoting cell survival, proliferation, migration, chemoresistance, and contributing to fibrosis and immunosuppression within the tumor microenvironment. Narmafotinib has demonstrated promising preclinical activity in models of cancer and fibrosis. It is being developed primarily for advanced pancreatic cancer (currently in Phase 2 trials) but also shows potential for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), where it has received Orphan Drug Designation from the FDA. The drug is being developed by Amplia Therapeutics.
- Other names
- narmafotinib
02
Targets
FAK (Focal adhesion kinase)
Beyond the preview
Go deeper on narmafotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on narmafotinib.